Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint

But Additional Survival Data Awaited

 
• By Jung Won Shin

Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.

clinical trials
Meeting Secondary Endpoints Will Increase Confidence In Tovecimig (Shutterstock)

More from South Korea

More from R&D